Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Real Patient Case Studies Case Study #1: Executive Recovery and Body Recomposition Patient: 47-year-old male tech executive Chief Complaints: Poor recovery from workouts, increasing abdominal fat despite consistent exercise, declining sleep quality, mental fog Baseline Labs: IGF-1: 142 ng/mL (low for age) Testosterone: 387 ng/dL (low-normal) Body fat: 26% (DEXA) Visceral fat area: 187 cm (elevated risk) hs-CRP: 3.2 mg/L (elevated inflammation) Treatment Protocol: Weeks 1-4: Optimize testosterone to 700+ ng/dL using testosterone cypionate, address vitamin D deficiency (was 24 ng/mL) Weeks 5-20: Add sermorelin 300 mcg nightly, 6 days/week Weeks 21-32: Add tesamorelin 2 mg daily to target stubborn visceral fat 32-Week Results: IGF-1: 267 ng/mL (+89%) Body fat: 18.5% (-7.5 percentage points) Lean mass: +6.8 kg gained Visceral fat area: 98 cm (-48% reduction) hs-CRP: 0.8 mg/L (normalized) Sleep: Improved from 5.5 to 7.2 hours average, with 23% increase in deep sleep (Whoop tracking) Patient Report: The combination of testosterone optimization and peptides was transformative
Whats Next After GLP-1
It penetrates the mitochondrial membrane and helps maintain its integrity and function
Zhang J, McCullough PA (2016) Lipoic acid in the prevention of acute kidney injury
One GLP-1 drug, known as albiglutide, which was withdrawn from the market with only a modest effect on weight loss, nonetheless reduced the rates of major adverse cardiovascular events by 22%
Beyond this, environmental toxins in the air we breathe, including ozone, nitrogen oxides (from smog), mineral dusts (e.g
